Canadian research buyers often search retatrutide vs tirzepatide canada and retatrutide vs semaglutide when they need to pick a catalogue SKU for a receptor-focused experiment. The useful comparison is structural: which receptors each compound engages. Outcome claims, dosing schedules, and consumer use-case ranking do not belong on a research listing.
Research use only (RUO). These materials are not for human consumption. They are not approved by Health Canada as medicines. Vancouver Island Peptides (VIP) lists them for laboratory research, with domestic British Columbia synthesis at our Vancouver lab partner and Canada-wide shipping in plain packaging.
Use this table as the only head-to-head frame on this page. It describes known agonist targets discussed in the research literature for each molecule class. It does not rank compounds, predict experimental results, or imply clinical use.
| Compound | Receptor targets (research literature) | Agonist class (short) | VIP product page |
|---|---|---|---|
| Semaglutide | GLP-1 | Single agonist | Semaglutide Canada |
| Tirzepatide | GLP-1 + GIP | Dual agonist | Tirzepatide Canada |
| Retatrutide | GLP-1 + GIP + glucagon | Triple agonist | Retatrutide Canada |
That is the comparison. Everything else on this page is catalogue, documentation, and fulfilment context for Canadian labs.
GLP-1 (glucagon-like peptide-1 receptor). Semaglutide is the single-agonist reference in this set. Labs that need a GLP-1-only tool often start here so control arms stay simple.
GLP-1 + GIP (glucose-dependent insulinotropic polypeptide receptor). Tirzepatide adds a second incretin-related target. Dual-agonist designs are useful when the protocol requires concurrent GLP-1 and GIP pathway coverage in the same molecule.
GLP-1 + GIP + glucagon receptor. Retatrutide adds glucagon-receptor engagement on top of the dual incretin profile. Triple-agonist work needs clear notebook notes that all three targets are in play; do not treat Retatrutide as a drop-in synonym for Semaglutide or Tirzepatide.
None of these labels is a therapy recommendation. They are classification tags for research planning and inventory.
VIP synthesizes listed research peptides at a Vancouver, BC lab partner rather than importing finished vials for relabel. Current pack options (confirm live pages before ordering):
Browse the full set on the Canadian research peptide catalogue. Prices are in CAD. Payment at checkout is Interac e-Transfer for orders under $500; BTC or USDC (on Ethereum) for orders of $500 and over. Orders ship Canada-wide from a Canadian fulfilment path in discreet packaging; provincial transit times vary.
Analytical coverage is published on /lab-reports/. Reports describe the tested sample only. They do not prove clinical safety, product origin, or that your shipment matches that sample. Report IDs are not lot numbers.
As of the live index review for this draft:
Open the matching product page and the lab-reports index, save the PDF you rely on, and record the report ID plus download date in your lab notebook. If a strength you need has no public file, treat that as a documentation gap, not as implied purity.
Keep the decision documentary and experimental, not outcome-based:
If two compounds fit the receptor plan, pick the SKU with clearer documentation for the strength you need. That is a sourcing choice, not a claim that one molecule is “better.”
Staff will not advise dosing, reconstitution for personal use, or consumer “protocols.” Reconstitution and handling questions, when answered at all, belong in controlled lab-procedure language for qualified researchers.
Research products only. Not for human consumption. Not approved by Health Canada. Not intended to diagnose, treat, cure, or prevent any disease. Analytical reports, where published, describe the tested sample only.